Minutes – ERYTECH Combined General Meeting of June 24, 2022 – 06/24/2022 at 10:05 p.m.

MINUTES – GENERAL ASSEMBLY

MIXED

of

ERYTECH DU 2

4

JUNE

2022

Lyon (France), and Cambridge, MA (US)

the

24

June

2

022

–

L’

HAS

General meeting of

ERYTECH

Pharmaceuticals (Euronext

&

Nasdaq: ERYP), a clinical-stage biopharmaceutical company that develops innovative therapies by encapsulating drugs in red blood cells (RBCs),

its

meeting today,

June 24, 2022.

The General Assembly approved all the resolutions supported by the Board of Directors, including:

• Approval of the parent company financial statements and consolidated financial statements for the fiscal year ended December 31, 2021;

• Allocation of income ;

• Approval of the special report of the statutory auditors on regulated agreements and commitments;

• Approval of the elements making up the total compensation and benefits of any kind, paid during or granted for the financial year ended December 31, 2021 to Gil BEYEN, Chief Executive Officer and to Jean-Paul KRESS, Chairman of the Board of Directors;

• Approval of the compensation policy for executive corporate officers and directors;

• Renewal of the directorships of:

  • Jean-Paul KRESS

  • Gil BEYEN

  • Philippe Archinard

  • Luc DOCHEZ

  • Sven ANDRÉASSON following the ratification of his appointment by cooptation

• Renewal of the mandate of KPMG SA as joint Statutory Auditor

• Approval of the regulations for the stock subscription and/or purchase option plan adopted by the Board of Directors on July 27, 2021;

• Delegations to the Board of Directors with a view to issuing shares or other securities giving access to shares to be issued immediately or in the future by the Company, with or without maintenance of shareholders’ preferential subscription rights;

• Authorizations to the Board of Directors to grant free shares, subscription and/or purchase options for Company shares and/or share subscription warrants, to corporate officers and employees of the Company or of companies in the ERYTECH Pharma Group.

The full results of all the resolutions voted on at the General Meeting can be viewed on the Company’s website (www.erytech.com) under Investors/General Meeting/2022.

About ERYTECH and eryaspase

(GRASPA®)

www.erytech.com

Founded in Lyon in 2004, ERYTECH is a clinical-stage biopharmaceutical company that develops innovative therapies based on red blood cells to fight against cancers and orphan diseases. Leveraging its proprietary ERYCAPS® platform, an innovative technology for encapsulating drugs in red blood cells, ERYTECH is developing a portfolio of product candidates targeting markets with significant unmet medical needs. ERYTECH mainly focuses on the development of products targeting metabolic disturbances in cancer cells, in order to deprive them of the amino acids necessary for their growth and survival.

The Company’s lead product, eryaspase (GRASPA®), consisting of L-asparaginase encapsulated in red blood cells from donors, addresses the altered asparagine and glutamine metabolism of cancer cells. The proof of concept of eryaspase as a metabolic agent against cancer has been established in different trials on acute lymphoblastic leukemia (ALL) and pancreatic cancer. A phase 2 investigator-sponsored study (IST) evaluating the use of eryaspase in patients with ALL who developed hypersensitivity reactions to pegylated asparaginase recently showed positive results, based on which the Company intends to file for approval in the United States and potentially in other territories. A Phase 2 study in metastatic triple-negative breast cancer and an investigator-sponsored Phase 1 clinical study in the first-line treatment of advanced pancreatic cancer are ongoing.

Eryaspase has received Fast Track Designation from the U.S. Food and Drug Administration (FDA) for the treatment of patients with acute lymphoblastic leukemia (ALL) who have developed hypersensitivity reactions to pegylated asparaginase and for the treatment of cancer of the advanced pancreas. The FDA and the European Medicines Agency have granted eryaspase orphan drug status for the treatment of ALL and pancreatic cancer. Eryaspase is not approved in any country.

ERYTECH produces its drug candidates for the treatment of patients in Europe at its GMP-compliant production site in Lyon, France, and believes it has the means to produce for patients in the United States thanks to its long-term supply agreement with Catalent, operating from ERYTECH’s former GMP production site in Princeton, New Jersey, USA.

ERYTECH is listed on the Nasdaq Global Select Market in the United States (symbol: ERYP) and on the Euronext regulated market in Paris (ISIN code: FR0011471135; symbol: ERYP). ERYTECH is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indices.

CONTACTS

Attachment

• CP_ERYTECH_2022 General Assembly CR_vf